Ocrelizumab vs placebo
Number of participants with new or enlarging T2‐hyperintense lesions on MRI · primary progressive multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found